Adult-onset nephrotic syndrome following coronavirus disease vaccination

Biradar, Vivek; Konnur, Abhijit; Gang, Sishir; Hegde, Umapati; Rajapurkar, Mohan; Patel, Hardik; Pandey, Sachida Nand; Soni, Shailesh

doi:10.1093/ckj/sfab153

Cited by 14 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several cases of MCD were described in the context of the ChAdOx1 vaccine (192)(193)(194). All these cases presented with a clinical picture of nephrotic syndrome that started up to 15 days after the first dose of the vaccine.…”

Section: Chadox1 (Astrazeneca) and MCDmentioning

confidence: 99%

COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review

et al. 2022

View full text Add to dashboard Cite

Despite their proven efficacy and huge contribution to the health of humankind, vaccines continue to be a source of concern for some individuals around the world. Vaccinations against COVID-19 increased the number of distressed people and intensified their distrust, particularly as the pandemic was still emerging and the populations were encouraged to be vaccinated under various slogans like “back to normal life” and “stop coronavirus”, goals which are still to be achieved. As fear of vaccination-related adverse events following immunization (AEFIs) is the main reason for vaccine hesitancy, we reviewed immune and autoimmune AEFIs in particular, though very rare, as the most worrisome aspect of the vaccines. Among others, autoimmune AEFIs of the most commonly administered COVID-19 vaccines include neurological ones such as Guillain-Barre syndrome, transverse myelitis, and Bell’s palsy, as well as myocarditis. In addition, the newly introduced notion related to COVID-19 vaccines, “vaccine-induced immune thrombotic thrombocytopenia/vaccine-induced prothrombotic immune thrombotic thrombocytopenia” (VITT/VIPITT)”, is of importance as well. Overviewing recent medical literature while focusing on the major immune and autoimmune AEFIs, demonstrating their rate of occurrence, presenting the cases reported, and their link to the specific type of COVID-19 vaccines represented the main aim of our work. In this narrative review, we illustrate the different vaccine types in current use, their associated immune and autoimmune AEFIs, with a focus on the 3 main COVID-19 vaccines (BNT162b2, mRNA-1273, and ChAdOx1). While the rate of AEFIs is extremely low, addressing the issue in this manner, in our opinion, is the best strategy for coping with vaccine hesitancy.

show abstract

Section: Chadox1 (Astrazeneca) and MCDmentioning

confidence: 99%

COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Recently, several cases of new-onset nephrotic syndrome after COVID-19 vaccination (Table 2) [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] have been reported from various countries. This indicates that the COVID-19 vaccine is used worldwide without regional differences; there is no gender or age difference with a wide age range (15-80 years).…”

Section: Discussionmentioning

confidence: 99%

New-onset Nephrotic Syndrome with Minimal Change Disease Following Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Literature Review

2023

J Vaccines Immunol

View full text Add to dashboard Cite

Background: Vaccination is underway in tremendous numbers worldwide while COVID-19 infection remains serious. Relapse of nephrotic syndrome following vaccination during the remission phase has been reported, and a causal relationship has been considered. However, new-onset nephrotic syndrome in the background of large-scale vaccinations over a short period of time may be incidental and unrelated to the vaccine.Case Presentatio: A 40-year-old Japanese woman with no history of kidney disease developed nephrotic syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine, which rapidly resolved with corticosteroid pulse therapy. She presented with a significant weight gain and anasarca 1 week after the vaccination. Laboratory examination revealed massive proteinuria (16.8 g/day) and severe hypoalbuminemia (1.2 g/dL). A renal biopsy revealed minimal change disease. She was treated with steroid pulse therapy and oral predonisolone (40 mg/day). She recovered completely 1 week after the steroid therapy. Throughout the course of her illness, no acute kidney injury or renal dysfunction were observed. Conclusion:Nephrotic syndrome is an extremely rare side effect when compared to the number of vaccinations; and it does not warrant witholding the vaccination as long as it is recognized that it is steroid-responsive.

show abstract

“…Five relapses and 3 "de novo" NS have been reported in association with the Astrazeneca ChAdOx1 [90][91][92][93]. Patients' characteristics and clinical details are the same as the patients group above (Table 4).…”

Section: Sars-cov-2 Adenovirusmentioning

confidence: 99%

Vaccines and nephrotic syndrome: efficacy and safety

et al. 2022

View full text Add to dashboard Cite

Vaccines represent the most important medical evolution in the last two centuries allowing prevention and formally eradication of a wide number of infectious diseases. Safety and effectiveness are main issues that still require an open discussion. A few clinical reports described a critical temporal relationship between vaccination and acute nephrotic syndrome, indirectly suggesting an association. For this review, the literature was reviewed to identify articles reporting associations of nephrotic syndrome with vaccines against a vast array of infectious diseases (including bacteria, virus and Sars-Cov-2). As specific aims, we evaluated effectiveness and safety in terms of occurrence of either “de novo” nephrotic syndrome in health subjects or “relapse” in those already affected by the disease. In total, 377 articles were found; 166 duplicates and 71 non-full text, animal studies or non-English language were removed. After excluding another 50 articles not containing relevant data on generic side effects or on relapses or new onset nephrotic syndrome, 90 articles met the search criteria. Overall, studies reported the effect of vaccines in 1015 patients, plus 4 nationwide epidemiologic investigations. Limited experience on vaccination of NS patients with measles, mumps, and rubella live attenuated vaccines does not allow any definitive conclusion on their safeness. VZV has been administered more frequently without side effects. Vaccines utilizing virus inactivated, recombinant, and toxoid can be utilized without risks in NS. Vaccines for influenza reduce the risk of infections during the pandemic and are associated with reduced risk of relapse of NS typically induced by the infection. Vaccines for SARS-CoV-2 (all kinds) offer a concrete approach to reduce the pandemic. “De novo” NS or recurrence are very rare and respond to common therapies.

show abstract

Adult-onset nephrotic syndrome following coronavirus disease vaccination

Cited by 14 publications

References 15 publications

COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review

COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review

New-onset Nephrotic Syndrome with Minimal Change Disease Following Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Literature Review

Vaccines and nephrotic syndrome: efficacy and safety

Contact Info

Product

Resources

About